Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has completed key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The announcement marks a significant step in integrating artificial intelligence into pharmaceutical production, with potential implications for efficiency, quality control, and cost reduction in drug manufacturing.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring, and autonomous materials movement. According to the company, the integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing. This integration could create opportunities in software licensing, automation deployment, manufacturing partnerships, and technology-enabled contract development and manufacturing services (CDMO).
Oncotelic’s initiative addresses a critical need in the pharmaceutical industry: the adoption of advanced automation and AI to streamline GMP compliance, reduce human error, and accelerate production timelines. As regulatory requirements become more stringent and the demand for sterile injectables grows, AI-powered platforms like PDAOAI(TM) could offer competitive advantages to manufacturers. The company plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio.
The successful completion of Phase 2 objectives brings Oncotelic closer to offering a technology-enabled CDMO service that could be licensed to other pharmaceutical manufacturers. This move aligns with broader industry trends toward digitization and automation in biopharmaceutical production. As Oncotelic prepares for the BIO International Convention 2026, the company is positioning itself as a potential leader in AI-driven GMP manufacturing, which could open new revenue streams and strategic partnerships.
For more information, visit the company’s newsroom at https://nnw.fm/OTLC and the full press release at https://nnw.fm/j1n43.
